Ocular Therapeutix Inc. reported a first‑quarter 2026 net loss of $88.6 million, or $0.40 per share, for the quarter ended March 31, 2026. Revenue rose 0.8% to $10.8 million from $10.7 million a year earlier, but the company still fell short of the consensus estimate of $12.7 million. Cash on hand was $666.7 million as of March 31, giving the company a runway that extends into 2028 under current spending assumptions.
The earnings miss was driven primarily by a sharp increase in research and development spending, which climbed to $66.2 million from $42.9 million a year earlier, and a rise in selling and marketing costs to $16.6 million from $14.1 million. The higher R&D outlay reflects intensified investment in the AXPAXLI program, including Phase 3 SOL‑1 data collection and preparation for a potential NDA submission. The modest revenue growth was insufficient to offset the cost escalation, resulting in a $0.08 EPS miss of roughly 25% against the consensus estimate of $-0.32.
Revenue was largely driven by the commercial product DEXTENZA, which contributed the bulk of the $10.8 million. The pipeline remains the company’s strategic focus, with AXPAXLI showing superior outcomes in the SOL‑1 Phase 3 trial for wet age‑related macular degeneration. The company’s leadership highlighted the trial’s durability and the potential for a 505(b)(2) NDA submission, underscoring the long‑term upside that offsets the short‑term financial drag.
Management emphasized the strength of the clinical data while acknowledging the current financial hit. "2026 is off to a tremendous start for Ocular, driven by the superiority demonstrated with AXPAXLI in the landmark SOL‑1 Phase 3 trial in wet AMD," said CEO Pravin U. Dugel. He added that the company remains on track to submit an NDA based on week‑52 data and that the $667 million cash balance provides a runway into 2028, though it does not cover the full commercialization costs of AXPAXLI.
The market reacted negatively, with the stock falling in pre‑market trading. Investors focused on the earnings miss and the revenue shortfall, which together signaled a wider net loss than expected. The negative reaction was amplified by the lack of forward guidance, leaving investors uncertain about near‑term revenue growth despite the promising pipeline.
Looking ahead, Ocular Therapeutix has not issued new revenue guidance for the next quarter or full year. The company’s emphasis remains on advancing AXPAXLI and other programs such as SOL‑R and HELIOS‑3, while maintaining a strong cash position that supports continued R&D investment and potential commercialization activities. The earnings miss highlights short‑term financial pressure, but the long‑term prospects hinge on the successful regulatory approval and market adoption of AXPAXLI.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.